Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCNS
MCID: LPD004
MIFTS: 51

Lipoid Nephrosis (MCNS)

Categories: Blood diseases, Nephrological diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lipoid Nephrosis

About this section

MalaCards integrated aliases for Lipoid Nephrosis:

Name: Lipoid Nephrosis 12 15 73
Minimal Change Disease 12 53
Nephrotic Syndrome with Lesion of Minimal Change Glomerulonephritis 12
Nephrotic Syndrome with Lesion of Minimal Change Nephrotic Syndrome 12
Idiopathic Minimal Change Nephrotic Syndrome 53
Glomerulonephritis, Minimal Change 73
Nephrotic Syndrome, Minimal Change 73
Minimal Change Glomerulonephritis 12
Minimal Change Nephrotic Syndrome 53
Nephrotic Syndrome Minimal Change 55
Minimal Change Glomerulopathy 53
Nephrosis, Lipoid 44
Mcns 53

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Nephrological diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:10966
ICD10 33 N04
MeSH 44 D009402
NCIt 50 C34844
SNOMED-CT 68 44785005
Sources

Summaries for Lipoid Nephrosis

About this section
NIH Rare Diseases : 53 Minimal change disease is a kidney disease in which there is damage to the filtering units of the kidney (glomeruli). It is the most common cause of nephrotic syndrome in children. Nephrotic syndrome is comprised of a group of symptoms including protein in the urine (proteinuria), low protein levels in the blood, high cholesterol and triglycerides, an increased risk for blood clots, and swelling. Other features of this disease include weight gain and a foamy appearance of the urine. The cause of minimal change disease is unknown, but it may occur following an allergic reaction or infection. Treatment may involve the use of steroids.

MalaCards based summary : Lipoid Nephrosis, also known as minimal change disease, is related to mesangial proliferative glomerulonephritis and focal segmental glomerulosclerosis. An important gene associated with Lipoid Nephrosis is NPHS1 (NPHS1, Nephrin), and among its related pathways/superpathways are NF-kappaB Signaling and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and skin, and related phenotypes are homeostasis/metabolism and mortality/aging

Wikipedia : 76 Minimal change disease (also known as MCD, minimal change glomerulopathy, and nil disease, among others)... more...

Sources

Related Diseases for Lipoid Nephrosis

About this section

Diseases related to Lipoid Nephrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 212)
# Related Disease Score Top Affiliating Genes
1 mesangial proliferative glomerulonephritis 31.9 CCL2 CD79A
2 focal segmental glomerulosclerosis 31.6 SYNPO NPHS2 NPHS1 CD2AP ALB
3 nephrotic syndrome 30.5 ALB CD2AP NPHS1 NPHS2
4 glomerulonephritis 30.4 NPHS2 NPHS1 CD79A CCL2 ALB
5 strongyloidiasis 30.2 CD79A IL13
6 microvascular complications of diabetes 3 30.0 ALB NPHS1
7 analbuminemia 29.9 ALB NPHS1 TF
8 tetanus 29.8 CD79A IL10 IL13
9 acute kidney tubular necrosis 29.8 ALB NAGLU
10 iga glomerulonephritis 29.2 SERPINB7 NPHS2 NPHS1 NAGLU CD79A CCL2
11 membranous nephropathy 28.9 TF SERPINB7 NPHS2 NPHS1 CD79A CD2AP
12 kidney disease 28.7 TF NPHS2 NPHS1 NAGLU CD2AP CCL2
13 c1q nephropathy 11.3
14 idiopathic steroid-sensitive nephrotic syndrome with minimal change 11.1
15 focal segmental glomerulosclerosis 1 10.4
16 ascaridiasis 10.3 IL10 IL13
17 nickel allergic contact dermatitis 10.3 IL10 IL13
18 trichuriasis 10.2 IL10 IL13
19 apple allergy 10.2 IL10 IL13
20 sporadic idiopathic steroid-resistant nephrotic syndrome with focal segmental hyalinosis 10.2 CD2AP NPHS2
21 nephrotic syndrome, type 6 10.2 NPHS1 NPHS2
22 eosinophilic meningitis 10.2 IL10 IL13
23 palladium allergic contact dermatitis 10.2 CCL2 IL10
24 hypoparathyroidism, sensorineural deafness, and renal disease 10.2 NPHS1 NPHS2
25 peanut allergy 10.2 IL10 IL13
26 fascioliasis 10.2 ALB IL10
27 fungal meningitis 10.2 CCL2 IL10
28 thrombosis 10.2
29 interstitial nephritis 10.2
30 mycoplasma pneumoniae pneumonia 10.2 IL10 IL13
31 epstein-barr virus hepatitis 10.2 ALB TF
32 food allergy 10.2 ALB IL10 IL13
33 ascending cholangitis 10.2 ALB CCL2
34 upper respiratory tract disease 10.2 ALB IL10 IL13
35 yellow nail syndrome 10.2 ALB TF
36 schistosomiasis 10.2 ALB IL10 IL13
37 immune system disease 10.2 ALB IL10 IL13
38 marasmus 10.2 ALB TF
39 kwashiorkor 10.1 ALB TF
40 kidney hypertrophy 10.1 ALB NPHS1 NPHS2
41 atrial septal defect 3 10.1 CD2AP NPHS1 NPHS2
42 familial idiopathic steroid-resistant nephrotic syndrome with focal segmental hyalinosis 10.1 CD2AP NPHS1 NPHS2
43 familial nephrotic syndrome 10.1 CD2AP NPHS1 NPHS2
44 nephrotic syndrome, type 1 10.1 CD2AP NPHS1 NPHS2
45 denys-drash syndrome 10.1 CD2AP NPHS1 NPHS2
46 hemorrhagic fever 10.1 ALB IL10
47 sporotrichosis 10.1 CD79A IL10
48 frasier syndrome 10.1 CD2AP NPHS1 NPHS2
49 nonspecific interstitial pneumonia 10.1 CCL2 IL13
50 lung disease 10.1 CCL2 IL10 IL13

Graphical network of the top 20 diseases related to Lipoid Nephrosis:



Diseases related to Lipoid Nephrosis
Sources

Symptoms & Phenotypes for Lipoid Nephrosis

About this section

MGI Mouse Phenotypes related to Lipoid Nephrosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.81 ALB CD2AP CD79A IL10 IL13 IL4R
2 mortality/aging MP:0010768 9.61 ALB CD2AP IL10 IL13 IL4R NAGLU
3 renal/urinary system MP:0005367 9.17 ALB CD2AP CD79A NAGLU NPHS1 NPHS2
Sources

Drugs & Therapeutics for Lipoid Nephrosis

About this section

Drugs for Lipoid Nephrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 83-43-2 6741
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-24-8 5755
3
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Not Applicable 302-25-0
4
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3 104987-11-3 445643 439492
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Not Applicable 2921-57-5
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 53-03-2 5865
7
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
8
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 1406-16-2
9
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Not Applicable 2920-86-7
10 Hormone Antagonists Phase 4,Phase 3,Not Applicable
11 Hormones Phase 4,Phase 3,Not Applicable
12 Immunoglobulin A Phase 4,Not Applicable
13 beta-endorphin Phase 4
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Not Applicable
15 Adrenocorticotropic Hormone Phase 4
16 Melanocyte-Stimulating Hormones Phase 4
17 Calcineurin Inhibitors Phase 4,Phase 2,Phase 3
18 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Not Applicable
19 Prednisolone acetate Phase 4,Phase 3,Not Applicable
20 glucocorticoids Phase 4,Phase 3,Not Applicable
21 Methylprednisolone acetate Phase 4,Phase 3,Not Applicable
22 Anti-Inflammatory Agents Phase 4,Phase 3,Not Applicable
23 Autonomic Agents Phase 4,Phase 3,Not Applicable
24 Neuroprotective Agents Phase 4,Not Applicable
25 Antiemetics Phase 4,Phase 3,Not Applicable
26 Peripheral Nervous System Agents Phase 4,Phase 3,Not Applicable
27 Gastrointestinal Agents Phase 4,Phase 3,Not Applicable
28 Immunologic Factors Phase 4,Phase 3,Phase 2
29 Protective Agents Phase 4,Not Applicable
30 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
31 Bone Density Conservation Agents Phase 4,Not Applicable
32 Micronutrients Phase 4,Not Applicable
33 Hydroxycholecalciferols Phase 4
34 Calciferol Phase 4,Not Applicable
35 Vitamins Phase 4,Not Applicable
36 Trace Elements Phase 4,Not Applicable
37
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
38
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
39
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
40
Mycophenolic acid Approved Phase 3 24280-93-1 446541
41
Valproic Acid Approved, Investigational Phase 2, Phase 3 99-66-1 3121
42 Antirheumatic Agents Phase 3,Phase 2
43 BB 1101 Phase 3
44
protease inhibitors Phase 3
45 HIV Protease Inhibitors Phase 3
46 Antibodies, Monoclonal Phase 3
47 Antibodies Phase 3,Not Applicable
48 Immunoglobulins Phase 3,Not Applicable
49 Anti-Infective Agents Phase 3
50 Anti-Bacterial Agents Phase 3

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4 ACTHAR gel
2 Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease Recruiting NCT00982072 Phase 4 tacrolimus;prednisolone
3 Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy Recruiting NCT03210688 Phase 4 Prednisolone;Alfacalcidol
4 Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS) Completed NCT00981838 Phase 3 Rituximab
5 Therapeutic Effect of Tacrolimus in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome Completed NCT01084980 Phase 2, Phase 3 Tacrolimus
6 Steroid Treatment for Kidney Disease Completed NCT00065611 Phase 3 Oral dexamethasone
7 Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome Completed NCT02438982 Phase 3 Tacrolimus;Rituximab
8 Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood Completed NCT01268033 Phase 2, Phase 3 Rituximab;Placebo
9 Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome Completed NCT01197040 Phase 3 Prednisone;acid mycophenolic (Myfortic)
10 Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Recruiting NCT03298698 Phase 3 Rituximab;Prednisone
11 Valproic Acid for Idiopathic Nephrotic Syndrome Recruiting NCT02896270 Phase 2, Phase 3 Valproic Acid
12 Podocyte Retinoids Completed NCT00098020 Phase 2 Isotretinoin
13 Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) Recruiting NCT02592798 Phase 2 Abatacept
14 A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases Completed NCT02639260 Phase 1 N-acetyl-mannosamine (ManNAc)
15 The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy Completed NCT01451710 Not Applicable Prednisone or Prednisolone
16 MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics Completed NCT02869893 Not Applicable Secretin
17 Kidney Disease Biomarkers Completed NCT00255398
18 Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients Completed NCT01470183
19 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study Completed NCT01663129
20 Nephrotic Syndrome Study Network Recruiting NCT01209000
21 Diagnostic Value of Linked Color Imaging for Minimal Change Esophagitis in Nonerosive Reflux Esophagitis and GERD Recruiting NCT03068572
22 Diagnostic and Prognostic Value of Miss-1 Study in Children and Adult With Nephrotic Syndrome MISSNEPHROTIQUE Recruiting NCT03592030
23 INSIGHT (Insight Into Nephrotic Syndrome) Recruiting NCT01605266
24 The Canadian Glomerulonephritis Registry and Translational Research Initiative Recruiting NCT03460054
25 Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure Recruiting NCT02194582
26 Study of The Association of Mutations in The NPHS2 Gene and Nephrotic Syndrome in Children and Adults in Middle East Active, not recruiting NCT03326037
27 Vitamin D Supplementation in Glomerular Disease Suspended NCT01835639 Not Applicable

Search NIH Clinical Center for Lipoid Nephrosis

Cochrane evidence based reviews: nephrosis, lipoid

Sources

Genetic Tests for Lipoid Nephrosis

About this section
Sources

Anatomical Context for Lipoid Nephrosis

About this section

MalaCards organs/tissues related to Lipoid Nephrosis:

41
Kidney, Bone, Skin, Lung, T Cells, Liver, Thyroid
Sources

Publications for Lipoid Nephrosis

About this section

Articles related to Lipoid Nephrosis:

(show top 50) (show all 350)
# Title Authors Year
1
Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. ( 29989000 )
2018
2
Adult-onset Minimal Change Disease with IgA Nephropathy and Hepatitis C. ( 29682437 )
2018
3
Rare Association of Waardenburg Syndrome with Minimal Change Disease. ( 29962674 )
2018
4
Abatacept efficacy in steroid-resistant minimal-change disease revealed by the speed of proteinuria reduction after the start of abatacept
. ( 29249233 )
2018
5
Monoclonal B lymphocytosis and minimal change disease: a new monoclonal B-cell disorder of renal significance? ( 29270844 )
2018
6
Increased PD-1+CD154+ Tfh cells are possibly the most important functional subset of PD-1+ T follicular helper cells in adult patients with minimal change disease. ( 29288900 )
2018
7
A diagnostic model for minimal change disease based on biological parameters. ( 29340242 )
2018
8
Nephrin Loss Can Be Used to Predict Remission and Long-term Renal Outcome in Patients With Minimal Change Disease. ( 29340328 )
2018
9
Minimal change disease with maximum immunosuppression: successful treatment of steroid-dependent minimal change disease with rituximab. ( 29437743 )
2018
10
miR-499 Ameliorates Podocyte Injury by Targeting Calcineurin in Minimal Change Disease. ( 29448244 )
2018
11
Minimal change disease of the kidney in a young Sprague Dawley rat. ( 29479141 )
2018
12
Urinary CD80: a biomarker for a favorable response to corticosteroids in minimal change disease. ( 29492674 )
2018
13
Urinary CD80 as a Replacement for Renal Biopsy for Diagnosis of Pediatric Minimal Change Disease. ( 29507273 )
2018
14
Acute aortoiliac thrombosis due to minimal change disease. ( 29520906 )
2018
15
Minimal change disease related to rifampicin presenting with acute renal failure during treatment for latent tuberculosis infection: A case report. ( 29851774 )
2018
16
Treatment patterns and steroid dose for adult minimal change disease relapses: A retrospective cohort study. ( 29912938 )
2018
17
Molecular and Cellular Mechanisms for Proteinuria in Minimal Change Disease. ( 29942802 )
2018
18
Minimal change disease associated with anti-PD1 immunotherapy: a case report. ( 29970032 )
2018
19
Minimal Change Disease Induced by Lorlatinib. ( 30049381 )
2018
20
CD80 and CTLA-4 as diagnostic and prognostic markers in adult-onset minimal change disease: a retrospective study. ( 30083478 )
2018
21
Adult minimal-change disease: observational data from a UK centre on patient characteristics, therapies, and outcomes. ( 30115013 )
2018
22
Respiratory Tract Infection: A Risk Factor for the Onset and Relapse of Adult-Onset Minimal Change Disease in Southern China. ( 30228981 )
2018
23
Minimal Change Disease Associated with Ingestion of Poison Sumac. ( 30288379 )
2018
24
Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis. ( 30360670 )
2018
25
Minimal change disease: A case report. ( 30531364 )
2018
26
Immunoglobulin E and G Levels in Predicting Minimal Change Disease before Renal Biopsy. ( 30534559 )
2018
27
Minimal Change Disease Associated with High-dose Aspirin. ( 30542627 )
2018
28
Short-Term Steroid Regimen for Adult Steroid-Sensitive Minimal Change Disease. ( 30557879 )
2018
29
Shortening the Duration of Corticosteroid Exposure in Minimal Change Disease: Can We Treat Adults Like Children? ( 30557880 )
2018
30
Impact of Τh1 and Τh2 cytokines in the progression of idiopathic nephrotic syndrome due to focal segmental glomerulosclerosis and minimal change disease. ( 28975100 )
2017
31
A case developing minimal change disease during the course of IgG4-related disease. ( 25736358 )
2017
32
Nephrotic syndrome due to minimal change disease secondary to spider bite: clinico-pathological case of a non-described complication of latrodectism. ( 28396739 )
2017
33
Syncope in a patient with minimal change disease without nephrotic-range proteinuria. ( 28679334 )
2017
34
Clinicopathological features, diagnosis, and treatment of IgA nephropathy with minimal change disease related to exposure to mercury-containing cosmetics: a case report
. ( 28102816 )
2017
35
Minimal Change Disease. ( 27940460 )
2017
36
Tacrolimus improves proteinuria remission in adults with cyclosporine A-resistant or -dependent minimal change disease. ( 28035723 )
2017
37
Tubular B7-1 expression parallels proteinuria levels, but not clinical outcomes in adult minimal change disease patients. ( 28150736 )
2017
38
Clinical trials in minimal change disease. ( 28391333 )
2017
39
Steroid Pulse Therapy for De Novo Minimal Change Disease During Pregnancy. ( 28416778 )
2017
40
Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies. ( 28540057 )
2017
41
The efficacy of rituximab in adult frequently relapsing minimal change disease. ( 28638601 )
2017
42
Analysis of T Cell Subsets in Adult Primary/Idiopathic Minimal Change Disease: A Pilot Study. ( 28894608 )
2017
43
50 Years Ago in TheJournal ofPediatrics: Effect of Cyclophosphamide on Lipoid Nephrosis in the Human and on Aminonucleoside Nephrosis in the Rat. ( 27017462 )
2016
44
IgM nephropathy: is it closer to minimal change disease or to focal segmental glomerulosclerosis? ( 26842624 )
2016
45
Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis. ( 27274821 )
2016
46
Nephrotic Syndrome without Hematuria due to Infection-Related Glomerulonephritis Mimicking Minimal-Change Disease in a Child. ( 26889476 )
2016
47
Vanishing Bile Duct Syndrome with Hemophagocytic Lymphohistiocytosis After Minimal Change Disease. ( 27316571 )
2016
48
Minimal change disease in a patient with myasthenia gravis: A case report. ( 27684864 )
2016
49
Minimal change disease: an unusual presentation of marginal zone MALT lymphoma. ( 26636329 )
2016
50
A Unique Cause of Proteinuria in Pregnancy: Class II Lupus Nephritis with Concomitant Minimal Change Disease. ( 27781205 )
2016
Sources

Variations for Lipoid Nephrosis

About this section
Sources

Expression for Lipoid Nephrosis

About this section
Search GEO for disease gene expression data for Lipoid Nephrosis.
Sources

Pathways for Lipoid Nephrosis

About this section

Pathways related to Lipoid Nephrosis according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
NF-kappaB Signaling 4
12.22 CCL2 CD2AP CD79A IL10
2
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.87 IL10 IL13 TF
3
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.75 CCL2 IL10 IL13 IL4R
4
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.4 CCL2 IL10 IL13
5
Interleukin-4 and 13 signaling 66
11.31 CCL2 IL10 IL13 IL4R
6
Interleukin-10 signaling 66
11.19 CCL2 IL10 IL13
7
Th2 Differentiation Pathway 65
11.1 IL10 IL13 IL4R
8
Cytokines and Inflammatory Response 1
10.97 IL10 IL13
9
G-protein signaling_RhoB regulation pathway 22
10.93 CCL2 IL10 IL13
10
OX40 Pathway 64
10.91 IL10 IL13
11
Nephrin interactions 66
10.8 CD2AP NPHS1
12
Primary Focal Segmental Glomerulosclerosis FSGS 1
10.79 CD2AP NPHS1 NPHS2 SYNPO
13
Nephrin/Neph1 signaling in the kidney podocyte 1
10.75 CD2AP NPHS1 NPHS2
Sources

GO Terms for Lipoid Nephrosis

About this section

Cellular components related to Lipoid Nephrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 ALB CCL2 IL10 IL13 IL4R SERPINB7
2 slit diaphragm GO:0036057 8.62 NPHS1 NPHS2

Biological processes related to Lipoid Nephrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.67 CCL2 IL10 IL13 IL4R
2 cytokine-mediated signaling pathway GO:0019221 9.56 CCL2 IL10 IL13 IL4R
3 B cell proliferation GO:0042100 9.4 CD79A IL10
4 defense response to protozoan GO:0042832 9.32 IL10 IL4R
5 positive regulation of mast cell degranulation GO:0043306 9.16 IL13 IL4R
6 positive regulation of immunoglobulin production GO:0002639 8.96 IL13 IL4R
7 positive regulation of macrophage activation GO:0043032 8.8 IL10 IL13 IL4R

Molecular functions related to Lipoid Nephrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 CCL2 IL10 IL13
Sources

Sources for Lipoid Nephrosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....